Literature DB >> 9725202

Beta-galactoside-binding protein (beta GBP) alters the cell cycle, up-regulates expression of the alpha- and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes.

A Allione1, V Wells, G Forni, L Mallucci, F Novelli.   

Abstract

In this paper, the effects of beta-galactoside binding protein (beta GBP), the LGALS1 gene product, on the cell cycle progression and expansion of activated human T lymphocytes were studied. Beta GBP drastically inhibits the IL-2 induced proliferation of PHA-activated T lymphocytes as well as the IL-2 independent proliferation of malignant T lymphocytes by arresting them in the S and G2/M phases of the cell cycle. In addition, beta GBP up-regulates the expression of both the alpha- and the beta-chains of the IFN-gamma R on activated T lymphocyte membrane. None of these effects depend on sugar binding: saturating amounts of lactose do not affect the cell cycle block nor IFN-gamma R up-modulation. The increased expression of both chains renders beta GBP-treated T lymphoblasts sensitive to IFN-y-induced apoptosis. Taken as a whole, these findings suggest that beta GBP plays an important immunoregulatory role by switching off T lymphocyte effector functions. They also provide the first evidence of up-modulation of IFN-gamma R expression on T lymphocytes by a negative cell growth regulator.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725202

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses.

Authors:  Gabriel A Rabinovich; Marta A Toscano; Juan M Ilarregui; Natalia Rubinstein
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Galectins in hematological malignancies.

Authors:  Yves St-Pierre
Journal:  Am J Blood Res       Date:  2011-09-07

4.  Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells.

Authors:  Feng Zhang; Minhua Zheng; Ying Qu; Jianfang Li; Jun Ji; Bo Feng; Aiguo Lu; Jianwen Li; Mingliang Wang; Bingya Liu
Journal:  Mol Biol Rep       Date:  2008-04-10       Impact factor: 2.316

Review 5.  Regulation of cellular homeostasis by galectins.

Authors:  Daniel K Hsu; Fu-Tong Liu
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 6.  Galectin-1: a bifunctional regulator of cellular proliferation.

Authors:  Ken Scott; Cristina Weinberg
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

7.  Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferation.

Authors:  Dolgor Baatar; Purevdorj B Olkhanud; Valerie Wells; Fred E Indig; Livio Mallucci; Arya Biragyn
Journal:  Brain Behav Immun       Date:  2009-06-09       Impact factor: 7.217

8.  Expression profiling of cancer-related galectins in acute myeloid leukemia.

Authors:  Asmaa A El Leithy; Reham Helwa; Magda M Assem; Nagwa H A Hassan
Journal:  Tumour Biol       Date:  2015-05-09

9.  Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis.

Authors:  G A Rabinovich; G Daly; H Dreja; H Tailor; C M Riera; J Hirabayashi; Y Chernajovsky
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

10.  Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.

Authors:  L Gerard Toussaint; Allan E Nilson; Jennie M Goble; Karla V Ballman; C David James; Florence Lefranc; Robert Kiss; Joon H Uhm
Journal:  Mol Cancer       Date:  2012-05-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.